Eagle Pharmaceuticals Inc.’s (EGRX) Ryanodex, which was turned down by the FDA for the proposed indication as a treatment of exertional heatstroke, in conjunction with external cooling methods in 2017, now awaits the regulatory decision on August 8, 2020, in its second attempt.Exertional heatstroke (EHS) is one of the most severe forms of heat-related illness and carries high rates of morbidity and mortality. This rare, sudden, and unpredictable disorder is characterized by core body temperature of 104° F (40° C) or greater and significant neurological dysfunction, such as sudden changes in behavior, seizures, or coma.Ryanodex is already approved for the treatment of malignant hyperthermia in conjunction with appropriate supportive measures, and for the prevention of malignant hyperthermia in patients at high risk.The annual product sales of Ryanodex were $13 million in 2019 compared to $20 million in 2018.EGRX closed Friday’s (Jul.24, 2020) trading at $47.67, down 2.48%.